VaxGen plans to relist shares

South San Francisco biopharmaceutical firm VaxGen Inc. (Pink sheets: VXGN) said it is now current on its financial reporting obligations with the U.S. Security and Exchange Commission and plans to relist its common stock on a nationally recognized stock exchange.

VaxGen has suffered a series of setbacks.

The company, which suffered a well publicized failure of an AIDS vaccine it was developing in 2003, was delisted from the Nasdaq exchange in 2004 for failing to promptly file financial reports with federal authorities as required. It then lost a U.S. government contract to provide an anthrax vaccine in December 2006 after missing a key deadline.

businessBusiness & Real Estate

If you find our journalism valuable and relevant, please consider joining our Examiner membership program.
Find out more at www.sfexaminer.com/join/

Just Posted

Sergeant cleared in shooting of man on meth ‘rampage’

A San Francisco police sergeant has been cleared of criminal wrongdoing for… Continue reading

Protected bike lane, safety measures proposed for dangerous stretch of Folsom Street

Folsom Street between Second and Fifth streets has been the site of… Continue reading

Giants to host first leg of Bay Bridge Series

Among the changes made to the Major League Baseball schedule this year… Continue reading

Heat wave expected to hit the Bay Area this weekend

Much of the Bay Area and Monterey Bay region will face excessive… Continue reading

California’s eviction ban is ending. Gov. Newsom and lawmakers have 3 weeks to extend it

California Gov. Gavin Newsom and state lawmakers face an 18-day deadline to… Continue reading

Most Read